Literature DB >> 21847082

FSL constructs: a simple method for modifying cell/virion surfaces with a range of biological markers without affecting their viability.

Deborah A Blake1, Nicolai V Bovin, Dan Bess, Stephen M Henry.   

Abstract

The ability to modify/visualize biological surfaces, and then study the modified cell/virion in a range of in vitro and in vivo environments is essential to gaining further insight into the function of specific molecules or the entire entity. Studies of biological surface modification are generally limited to genetic engineering of the organism or the covalent attachment of chemical moieties to the cell surface(1,2). However these traditional techniques expose the cell to chemical reactants, or they require significant manipulation to achieve the desired outcome, making them cumbersome, and they may also inadvertently affect the viability/functionality of the modified cell. A simple method to harmlessly modify the surface of cells is required. Recently a new technology, KODE Technology has introduced a range of novel constructs consisting of three components: a functional head group (F), a spacer (S) and a lipid tail (L) and are known as Function-Spacer-Lipid or FSL constructs3. The spacer (S) is selected to provide a construct that is dispersible in water, yet will spontaneously and stably incorporate into a membrane. FSL construct functional moieties (F) so far include a range of saccharides including blood group-related determinants, sialic acids, hyaluronan polysaccharides, fluorophores, biotin, radiolabels, and a range of peptides(3-12). FSL constructs have been used in modifying embryos, spermatozoa, zebrafish, epithelial/endometrial cells, red blood cells, and virions to create quality controls systems and diagnostic panels, to modify cell adhesion/ interaction/ separation/ immobilization, and for in vitro and in vivo imaging of cells/virions(3-12). The process of modifying cells/virions is generic and extremely simple. The most common procedure is incubation of cells (in lipid free media) with a solution for FSL constructs for 1-2 hours at 37°C(4-10). During the incubation the FSL constructs spontaneously incorporate into the membrane, and the process is complete. Washing is optional. Cells modified by FSL constructs are known as kodecytes(6-9), while virions are kodevirions(10). FSL constructs as direct infusions and kodecytes/kodevirions have been used in experimental animal models(7,8,10). All kodecytes/kodevirions appear to retain their normal vitality and functionality while gaining the new function of the F moiety(7,8,10,11). The combination of dispersibility in biocompatible media, spontaneous incorporation into cell membranes, and apparent low toxicity, makes FSL constructs valuable research tools for the study of cells and virions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21847082      PMCID: PMC3211133          DOI: 10.3791/3289

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  9 in total

Review 1.  Chemical modification of viruses and virus-like particles.

Authors:  E Strable; M G Finn
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

Review 2.  Modification of red blood cells for laboratory quality control use.

Authors:  Stephen M Henry
Journal:  Curr Opin Hematol       Date:  2009-11       Impact factor: 3.284

3.  Fluorescein and radiolabeled Function-Spacer-Lipid constructs allow for simple in vitro and in vivo bioimaging of enveloped virions.

Authors:  Elizabeth M Hadac; Mark J Federspiel; Evgeny Chernyy; Alexander Tuzikov; Elena Korchagina; Nicolai V Bovin; Stephen Russell; Stephen M Henry
Journal:  J Virol Methods       Date:  2011-06-14       Impact factor: 2.014

4.  A synthetic globotriaosylceramide analogue inhibits HIV-1 infection in vitro by two mechanisms.

Authors:  Amanda L Harrison; Martin L Olsson; R Brad Jones; Stephanie Ramkumar; Darinka Sakac; Beth Binnington; Stephen Henry; Clifford A Lingwood; Donald R Branch
Journal:  Glycoconj J       Date:  2010-06-26       Impact factor: 2.916

5.  In vivo neutralization of anti-A and successful transfusion of A antigen-incompatible red blood cells in an animal model.

Authors:  Caroline Oliver; Deborah Blake; Stephen Henry
Journal:  Transfusion       Date:  2011-05-20       Impact factor: 3.157

6.  Modeling transfusion reactions and predicting in vivo cell survival with kodecytes.

Authors:  Caroline Oliver; Deborah Blake; Stephen Henry
Journal:  Transfusion       Date:  2011-02-08       Impact factor: 3.157

7.  Synthetic glycolipid modification of red blood cell membranes.

Authors:  Tom Frame; Tim Carroll; Elena Korchagina; Nicolai Bovin; Stephen Henry
Journal:  Transfusion       Date:  2007-05       Impact factor: 3.157

8.  Novel antibody screening cells, MUT+Mur kodecytes, created by attaching peptides onto red blood cells.

Authors:  Damien Heathcote; Tim Carroll; Jui-Jen Wang; Robert Flower; Igor Rodionov; Alexander Tuzikov; Nicolai Bovin; Stephen Henry
Journal:  Transfusion       Date:  2009-11-11       Impact factor: 3.157

Review 9.  Engineering targeted viral vectors for gene therapy.

Authors:  Reinhard Waehler; Stephen J Russell; David T Curiel
Journal:  Nat Rev Genet       Date:  2007-07-03       Impact factor: 53.242

  9 in total
  12 in total

1.  Fluorescent function-spacer-lipid construct labelling allows for real-time in vivo imaging of cell migration and behaviour in zebrafish (Danio rerio).

Authors:  Chuan-Ching Lan; Deborah Blake; Stephen Henry; Donald R Love
Journal:  J Fluoresc       Date:  2012-03-22       Impact factor: 2.217

2.  Cell surface glycoengineering improves selectin-mediated adhesion of mesenchymal stem cells (MSCs) and cardiosphere-derived cells (CDCs): Pilot validation in porcine ischemia-reperfusion model.

Authors:  Chi Y Lo; Brian R Weil; Beth A Palka; Arezoo Momeni; John M Canty; Sriram Neelamegham
Journal:  Biomaterials       Date:  2015-09-25       Impact factor: 12.479

Review 3.  Engineering the Surface of Therapeutic "Living" Cells.

Authors:  Jooyeon Park; Brenda Andrade; Yongbeom Seo; Myung-Joo Kim; Steven C Zimmerman; Hyunjoon Kong
Journal:  Chem Rev       Date:  2018-01-16       Impact factor: 60.622

4.  PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.

Authors:  Mulu Z Tesfay; Amber C Kirk; Elizabeth M Hadac; Guy E Griesmann; Mark J Federspiel; Glen N Barber; Stephen M Henry; Kah-Whye Peng; Stephen J Russell
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

5.  Labeling of influenza viruses with synthetic fluorescent and biotin-labeled lipids.

Authors:  Natalia A Ilyushina; Evgeny S Chernyy; Elena Y Korchagina; Aleksandra S Gambaryan; Stephen M Henry; Nicolai V Bovin
Journal:  Virol Sin       Date:  2014-07-31       Impact factor: 4.327

6.  Directing and Potentiating Stem Cell-Mediated Angiogenesis and Tissue Repair by Cell Surface E-Selectin Coating.

Authors:  Zhao-Jun Liu; Pirouz Daftarian; Letícia Kovalski; Bo Wang; Runxia Tian; Diego M Castilla; Emre Dikici; Victor L Perez; Sapna Deo; Sylvia Daunert; Omaida C Velazquez
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

7.  Ultra-Fast Glyco-Coating of Non-Biological Surfaces.

Authors:  Eleanor Williams; Katie Barr; Elena Korchagina; Alexander Tuzikov; Stephen Henry; Nicolai Bovin
Journal:  Int J Mol Sci       Date:  2016-01-16       Impact factor: 5.923

8.  Obtaining control of cell surface functionalizations via Pre-targeting and Supramolecular host guest interactions.

Authors:  Mark T M Rood; Silvia J Spa; Mick M Welling; Jan Bart Ten Hove; Danny M van Willigen; Tessa Buckle; Aldrik H Velders; Fijs W B van Leeuwen
Journal:  Sci Rep       Date:  2017-01-06       Impact factor: 4.379

9.  Fluorescence molecular painting of enveloped viruses.

Authors:  Christoph Metzner; Feliks Kochan; John A Dangerfield
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

Review 10.  Biomedical applications of glycosylphosphatidylinositol-anchored proteins.

Authors:  Susanne Heider; John A Dangerfield; Christoph Metzner
Journal:  J Lipid Res       Date:  2016-08-19       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.